Cabaletta Bio Stock News

Shareholder Action Notice: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm

SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Oct. 21,…

NEW YORK, March 3, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cabaletta investors who were…

SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.

LE AD PLAINTIFF DEADLINE IS APRIL 29, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CABA #CABA--The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, March 2, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain of its officers, on behalf of shareholders…

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Cabaletta securities between October 24, 2019 and December 13, 2021, both dates included (the “Class Period”

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ca

Cabaletta Bio (CABA) stock edged 3% higher premarket after the FDA granted Fast Track Designation for MuSK-CAART for patients with MuSK antibody-positive myasthenia gravis.

PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p

Cabaletta Bio Inc (CABA) shares closed today 10.3% lower than it did at the end of yesterday. The stock is currently down 8.4% year-to-date, down 73.9% over the past 12 months, and down 65.3% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $4.07 and as low as $3.45 this week.Shares closed 76.8% below its 52-week high and 13.8% above its 52-week low.Trading volume this week was 4.1% higher than the 10-day average and 85.1% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 430.8% The company's stock price performance over the past 12 months lags the peer average by 144.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Oxford Biomedica PLC said it signed a new license and supply agreement for its lentiviral vector delivery platform LentiVector with US biotech company Cabaletta Bio, Inc, which is developing engineere

The heavy selling pressure might have exhausted for Cabaletta Bio, Inc. (CABA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street